{"id":"ultra-rapid-lispro-urli","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"URLi is a modified form of insulin lispro designed with faster absorption kinetics through the addition of nulisinon (a surfactant) and citrate, enabling more rapid onset of action compared to standard insulin lispro. This allows for improved postprandial glucose control with dosing closer to meal initiation in patients with diabetes.","oneSentence":"Ultra Rapid Lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:37:03.689Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06600776","phase":"PHASE4","title":"Mealtime or Post-meal Dosing of URLi in Medtronic 780G Hybrid Closed Loop System","status":"NOT_YET_RECRUITING","sponsor":"Tel-Aviv Sourasky Medical Center","startDate":"2024-10-06","conditions":"Type 1 Diabetes (T1D)","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":40,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lyumjev"],"phase":"marketed","status":"active","brandName":"Ultra Rapid Lispro (URLi)","genericName":"Ultra Rapid Lispro (URLi)","companyName":"Tel-Aviv Sourasky Medical Center","companyId":"tel-aviv-sourasky-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ultra Rapid Lispro is a rapid-acting insulin analog that binds to insulin receptors to facilitate glucose uptake and utilization in peripheral tissues. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}